Circulating concentrations of monocyte chemoattractant protein-1 are associated with menopause status in Korean women

Clinica Chimica Acta

Volumn 403, Issue 1-2, 2009, Pages 92-96

  Park, Kang Seo ^a   Ahn, Kyu Jeung ^b   Kim, Byung Joon ^a   Kim, Hyun Jin ^a   Yoo, Seung Min ^a   Kim, Ju Young ^a   Lee, Ki Ho ^a   Baik, Haing Woon ^a   Lee, Seong Kyu ^a  

^a Eulji University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Circulating MCP 1; Insulin resistance; Menopause; Obesity; Women

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; INSULIN RESISTANCE; KOREA; MENOPAUSE; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMOKINE CCL2; FEMALE; HUMANS; INSULIN RESISTANCE; KOREA; MENOPAUSE; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PREMENOPAUSE;

EID: 64849087765     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.01.025     Document Type: Article

References (45)

1. Robinson E.A., Yoshimura T., Leonard E.J., et al. Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions. Proc Natl Acad Sci USA 86 (1989) 1850-1854
2. Kurihara T., and Bravo R. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J Biol Chem 271 (1996) 11603-11607
3. Reape T.J., and Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 147 (1999) 213-225
4. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 95 (2004) 858-866
5. Kamei N., Tobe K., Suzuki R., et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281 (2006) 26602-26614
6. Weisberg S.P., Hunter D., Huber R., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116 (2006) 115-124
7. Sartipy P., and Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100 (2003) 7265-7270
8. Takahashi K., Mizuarai S., Araki H., et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 278 (2003) 46654-46660
9. Sell H., and Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol 18 (2007) 258-262
10. Bruun J.M., Lihn A.S., Pedersen S.B., and Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 90 (2005) 2282-2289
11. Christiansen T., Richelsen B., and Bruun J.M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 29 (2005) 146-150
12. Kim C.S., Park H.S., Kawada T., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30 (2006) 1347-1355
13. Malavazos A.E., Cereda E., Morricone L., Coman C., Corsi M.M., and Ambrosi B. Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. Eur J Endocrinol 153 (2005) 871-877
14. Nomura S., Shouzu A., Omoto S., Nishikawa M., and Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 121 (2000) 437-443
15. Herder C., Baumert J., Thorand B., et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 49 (2006) 921-929
16. Mine S., Okada Y., Tanikawa T., Kawahara C., Tabata T., and Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun 344 (2006) 780-785
17. Piemonti L., Calori G., Mercalli A., et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 26 (2003) 2883-2889
18. Simeoni E., Hoffmann M.M., Winkelmann B.R., et al. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia 47 (2004) 1574-1580
19. Deepa R., Velmurugan K., Arvind K., et al. Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 55 (2006) 1232-1238
20. Kannel W.B., Hjortland M.C., McNamara P.M., and Gordon T. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med 85 (1976) 447-452
21. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., and Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med 321 (1989) 641-646
22. Kochaneck K.D., Murphy S.L., Andersson R.N., and Scott C. Deaths: final data for 2002. Natl Vital Stat Rep 53 (2004) 1-115
23. Palacios S., Borrego R.S., and Forteza A. The importance of preventive health care in post-menopausal women. Maturitas 52 Suppl 1 (2005) S53-S60
24. Turgeon J.L., Carr M.C., Maki P.M., Mendelsohn M.E., and Wise P.M. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 27 (2006) 575-605
25. Jensen J., Nilas L., and Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 12 (1990) 321-331
26. Stevenson J.C., Crook D., and Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98 (1993) 83-90
27. Crook D. Interpreting the plasma lipoprotein profile of the postmenopausal women. In: Erkkola R. (Ed). The Menopause (2006), Elsevier, Oxford 33-40
28. Skrzypczak M., and Szwed A. Assessment of the body mass index and selected physiological parameters in pre- and post-menopausal women. Homo 56 (2005) 141-152
29. Skouby S.O., and Jespersen J. The effects of ageing and hormone replacement therapy on glucose metabolism. In: Erkkola R. (Ed). The Menopause (2006), Elsevier, Oxford 41-51
30. Gaspard U.J., Gottal J.M., and van den Brûle F.A. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 21 (1995) 171-178
31. Pfeilschifter J., Köditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23 (2002) 90-119
32. Cantatore F.P., Loverro G., Ingrosso A.M., et al. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheumatol 14 (1995) 157-160
33. Girasole G., Giuliani N., Modena A.B., Passeri G., and Pedrazzoni M. Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin Endocrinol (Oxf) 51 (1999) 801-807
34. Woodward M., Rumley A., Tunstall-Pedoe H., and Lowe G.D. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 104 (1999) 246-257
35. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
36. Koh K.K., Jin D.K., Yang S.H., et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 103 (2001) 1961-1966
37. Koh K.K., Son J.W., Ahn J.Y., et al. Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int J Cardiol 81 (2001) 43-50
38. Stork S., Baumann K., von Schacky C., and Angerer P. The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res 53 (2002) 642-649
39. Sumino H., Ichikawa S., Kasama S., et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 189 (2006) 436-442
40. Pantsulaia I., Trofimov S., Kobyliansky E., and Livshits G. Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. Cytokine 32 (2005) 117-123
41. World Health Organization. The Asia-Pacific perspective: Redefining obesity and its treatment. World Health Organization (2000), Geneva, Switzerland
42. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
43. Haffner S.M., Miettinen H., and Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 20 (1997) 1087-1092
44. Choi S.H., Ahn C.W., Cha B.S., et al. The prevalence of the metabolic syndrome in Korean adults: comparison of WHO and NCEP criteria. Yonsei Med J 46 (2005) 198-205
45. Ryu S., Sung K.C., Chang Y., Lee W.Y., and Rhee E.J. Spectrum of insulin sensitivity in the Korean population. Metabolism 54 (2005) 1644-1651